Trogenix

Human brain
#Cancer research #Gene therapy #Trogenix

First patient dosed in glioblastoma gene therapy trial 

The first patient has been dosed in the Phase I/II clinical trial of a gene therapy for glioblastoma (GBM).  TGX-007, developed by oncology company Trogenix, is a dual-payload adeno-associated virus (AAV)-based gene therapy.   TGX-007 harnesses Trogenix’s proprietary Synthetic Super-Enhancer (SSE) technology to exploit the core cancer cell identity. The… Read More

#Cancer Research #News

MRI showing glioblastoma
#Brain cancer #Gene therapy #Trogenix

Gene therapy could eradicate tumours in brain cancer 

An innovative gene therapy could achieve complete tumour elimination in brain cancer, data shows.  Biotechnology company Trogenix has announced the publication of breakthrough preclinical data, reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM).  The results, published in … Read More

#Cancer Research #News

#Cancer biology #Genetic diseases #Regenerative Medicine #Stem cells #Trogenix

Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion, and transcriptional plasticity that allow tumours to survive and evolve. Steve Pollard, CSO & Founder of Trogenix and Professor of Stem Cell and Cancer Biology,… Read More

#Cancer Research #Exclusive Content